Apoptotic impact of α1‐blockers on prostate cancer growth: A myth or an inviting reality?
- 25 November 2003
- journal article
- review article
- Published by Wiley in The Prostate
- Vol. 59 (1), 91-100
- https://doi.org/10.1002/pros.10357
Abstract
BACKGROUND Pharmacological manipulation or genetic targeting of the major apoptosis regulators, such as bcl‐2, caspases, and inhibitors of apoptosis (IAPs), represent clinically attractive avenues towards effective therapeuti strategies for advanced prostate cancer. A wealth of evidence established the α1‐adrenoceptor antagonists to be clinically effective in relieving the symptoms associated with benign prostatic hyperplasia (BPH) by relaxing prostatic smooth muscle tone. This action alone however does not fully account for the long‐term clinical response to these drugs in BPH patients. METHODS Experimental and retrospective clinical studies provided new evidence supporting a differential growth‐suppressing function of two α1‐adrenoceptor antagonists against prostate cancer, independent of an α1‐adrenoceptor mechanism. RESULTS The quinazoline‐based antagonists, doxazosin and terazosin, induce apoptosis, inhibit cell adhesion to the extracellular matrix (by activating anoikis), and prevent cell invasion and migration of prostate tumor epithelial cells and vascular endothelial cells. Tamsulosin, a sulphonamide‐based, clinically effective α1‐adrenoceptor antagonist for BPH treatment, fails to exert a similar apoptotic action against prostate cells. Furthermore, at pharmacologically relevant doses, doxazosin suppresses benign and malignant prostate growth in in vivo experimental models. The effect is characterized by three intriguing features: (a) it is mediated by an α1‐adrenoceptor‐independent action, (possibly related to the quinazoline nucleus); (b) it is targeted at the apoptotic process without affecting cell proliferation; and (c) the elevated apoptotic index correlated with symptom score improvement in BPH patients. CONCLUSIONS This evidence challenges conventional knowledge of the mechanism of action of α1‐adrenoceptor antagonists, and points to a new therapeutic value for these drugs by providing a differential molecular basis for their anti‐tumor efficacy. The present review focuses on the characterization of the apoptotic/anti‐angiogenic effect of quinazoline‐based α1‐adrenoceptor antagonists against prostate cancer cells and discusses the clinical significance of this action in the prevention and treatment of prostate cancer.Keywords
This publication has 67 references indexed in Scilit:
- The biology of VEGF and its receptorsNature Medicine, 2003
- What's new in the treatment of advanced prostate cancer?European Journal Of Cancer, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Signal Transduction by Cell Adhesion Receptors and the Cytoskeleton: Functions of Integrins, Cadherins, Selectins, and Immunoglobulin-Superfamily MembersAnnual Review of Pharmacology and Toxicology, 2002
- Anoikis mechanismsCurrent Opinion in Cell Biology, 2001
- Apoptosis in prostate carcinogenesisCell and tissue research, 2000
- Caspase-mediated Cleavage of Focal Adhesion Kinase pp125FAK and Disassembly of Focal Adhesions in Human Endothelial Cell ApoptosisThe Journal of Experimental Medicine, 1998
- Transforming growth factor β1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosinThe Prostate, 1997
- A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA.The Journal of cell biology, 1996
- Mechanism of activation of the TGF-β receptorNature, 1994